Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects With Different HRD Tumor Status and With Platinum-Sensitive, Relapsed, High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 1 Prior Line of Chemotherapy

Trial ID # NCT02983799; LIGHT
Phase II
Drug Class DNA Damage Repair Pathway Inhibitors: PARP
Drug Name Olaparib
Alternate Drug Names AZD2281, Lynparza
Drugs in Trial Olaparib
Eligible Participant

Platinum sensitive recurrent ovarian cancer

Patients Enrolled


Therapy Setting


Study Design

Open-Label, Non-randomized


ORR, DCR, PFS, evaluated per RECIST


Exploratory: HRD status; HRD+ defined by Myriad myChoice test score ≥ 42


gBRCA MUT (n=75): ORR: 69%; DCR: 96%; PFS: 11.0 months
sBRCA MUT (n=25): ORR: 64%; DCR: 100%; PFS: 10.8 months
HRD+ (excl. BRCA MUT, n=68): ORR: 29%; DCR: 79%; PFS: 7.2 months
HRD- (n=89): ORR: 10%; DCR: 75%; PFS: 5.4 months

Clinically Significant Adverse Events

Serious AE:
Grade 3-4 AE:


Olaparib treatment has activity across all cohorts with similar efficacy in the gBRCA MUT and sBRCA MUT cohorts. For non-BRCA MUT patients, longer median PFS and higher ORR are observed in the HRD+ cohort


Cadoo K et al. Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis. Gynecol Oncol (2022) 166(3):425-431

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.